BP 

Lipid Lowering Drug

Fenofibrate (Fenocap) is indicated for hyperlipidemias of type IIa, IIb, III, IV & V in patients who have not responded adequately to diet & other appropriate measures. 

Fenofibrate (Fenocap) is contraindicated in patients with hypersensitivity to Fenofibrate (Fenocap) , severe renal or hepatic impairment, existing gall bladder disease, breast feeding mothers, photosensitivity to ketoprofen. 

Fenofibrate (Fenocap) capsule 200 mg once daily is recommended as the dose for the treatment of primary hypercholesterolemia, hypertriglyceridemia or mixed hyperlipidemia. Absorption of Fenofibrate (Fenocap)  is increased by approximately 35% when administered with food.

Gastro-intestinal (e.g. nausea, anorexia, and gastric pain), pruritus, urticaria, impotence, headache, dizziness, vertigo, fatigue, hair loss, myotoxicity.

Special care needed in patients with renal disease, as progressive increases in serum creatinine concentration or failure to follow dosage guidelines may result in myotoxicity; discontinue if myotoxicity suspected or creatinine kinase concentration increases significantly. Liver function tests recommended every 3 months for first year. 

Fenocap (Fenofibrate) has been reported to potentiate the anticoagulant effects of warfarin. Also Fenofibrate (Fenocap) may increase the nephrotoxicity of cyclosporine. Due to a potential increase the risk of rhabdomyolysis, cautions should be taken against the use of Fenofibrate (Fenocap) with HMG-CoA reductase inhibitors unless the benefits outweigh the risks. However, the use of low-dose statins with Fenofibrate (Fenocap) appears to be well tolerated.

Fenocap Capsule: Each box containing 3x14\\\'s capsules in blister pack.